Selskabets formål er at besidde aktier og anparter og lignende ejerandele i andre selskaber som en anlægsinvestering, at fungere som finansieringsselskab for koncernens øvrige sel-skaber, at forvalte selskabets midler, samt at drive handel og industri herunder import og eksport. Endvidere har selskabet til formål at indkøbe human plasma fra de danske blod-banker og sælge lægemidler produceret heraf til de danske sygehuse.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 322.8 mio. | -43.3 mio. | 320.5 mio. | 79.5 mio. | 11 | |
CVR: 25361695
Previous names: ApS KBIL 9 NR. 2204, CSL DENMARK ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 19179079
CVR 30076478
CVR 37940844
CVR 29804095
CVR 20315407
Alexandros Sigalas joined the board
Marcelo Horacio Estrella left the board
The financial health of CSL BEHRING ApS shows signs of volatility, particularly evident in its recent performance. In 2025, the company reported a revenue of 322.8 million DKK but faced a significant loss of 43.3 million DKK, contrasting with the previous year’s profit of 11.5 million DKK on a revenue of 303.2 million DKK. While revenue has generally trended upward over the past five years, from 248.6 million DKK in 2022 to 322.8 million DKK in 2025, the sharp decline in profitability raises concerns about operational efficiency and cost management. Equity has decreased from 134.7 million DKK in 2024 to 79.5 million DKK in 2025, indicating potential financial instability. As a player in the wholesale trade of pharmaceuticals and healthcare products, the company must address these challenges to strengthen its position in the industry.
AI-generated summary
companydata.dk